Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT. (NL28394)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00970619
Recruitment Status : Completed
First Posted : September 2, 2009
Last Update Posted : March 6, 2020
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:

Rationale: Iliofemoral deep venous thrombosis (IFDVT) is associated with significant post thrombotic morbidity. The presence of both obstruction and reflux significantly increases the chances for development of post-thrombotic syndrome (PTS). Early thrombolysis may reduce the incidence of PTS as compared to treatment with conventional anticoagulant medication alone. Improvement of the health related quality of life (HRQOL) has been reported after surgical clot removal. The investigators hypothesize that such improvements could also be reached after catheter-directed thrombolysis (CDT).

Objective: To assess whether CDT for the treatment of IFDVT can safely and effectively reduce post-thrombotic morbidity after one year. The secondary objective is to study whether CDT intervention has a positive effect on the HRQOL of patients with IFDVT and to assess late PTS.

Study design: Prospective, multicenter, single-blind, allocation concealed, randomized controlled trial Study population: All consecutive patients with IFDVT presenting at the emergency or outpatient departments of the participating centers. The thrombus should not be older than 14 days at randomization.

Intervention: After randomization patients will be allocated to either conservative anticoagulant treatment or to CDT combined with conservative anticoagulant treatment.

Main study parameters/endpoints: The primary efficacy outcome is the proportion of PTS at one year; a decline in PTS incidence from 25% to 8% is anticipated. The secondary outcome is the Health related Quality of life. The principal safety outcome is major bleeding during anticoagulant therapy. Bleeding as well as events of recurrent thrombosis will be monitored. Measurements of markers of coagulation and inflammation will be performed during follow-up. After CDT the patency of the venous system in the affected lower limb will be assessed as well as the percentage of clot lysis. The development of late PTS during follow-up will also be monitored.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: For patients who are randomized to CDT a hospital stay for 24-96 hours is mandatory. All patients will undergo additional imaging by magnetic resonance venography and air phletysmography (if available) at baseline and after 12 months; blood will be taken at these visits. Clinical follow-up visits will be matching usual care at 3, 6, 12 months. Health-related quality of life (HRQOL) questionnaires will be filled out by all patients at baseline, 3, 6 and 12 months after the event; and once a year during the entire study duration. Further treatment will be in accordance with current guidelines for antithrombotic treatment. There may be an enhanced risk of bleeding in the thrombolysis group. The expected benefit is reduction of PTS from 25% to 8%, together with an improved quality of life.


Condition or disease Intervention/treatment Phase
Acute Thrombosis of Deep Veins of Proximal Lower Extremity Device: Ekos endowave system thrombolysis Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Ultrasound Accelerated Catheter-directed Thrombolysis for Primary Iliofemoral Deep Vein Thrombosis (IFDVT) Compared to Non-invasive Conventional Anticoagulant Therapy Alone: a Dutch Randomized Controlled Multicenter Clinical Trial
Actual Study Start Date : May 2010
Actual Primary Completion Date : November 2018
Actual Study Completion Date : November 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Conventional anticoagulation therapy
Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
Experimental: Ekos Endowave system thrombolysis
Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
Device: Ekos endowave system thrombolysis
Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
Other Name: Ekos endowave ® system




Primary Outcome Measures :
  1. Post thrombotic syndrome (percentage of patients with PTS) one year following the acute thrombotic event. [ Time Frame: one year ]

Secondary Outcome Measures :
  1. The Health Related Quality of Life (HRQOL) [ Time Frame: 5 years ]
  2. PTS during follow-up [ Time Frame: 5 years ]
  3. Recurrent venous thrombo-embolisms (VTE): DVT/Pulmonary Embolism during follow-up [ Time Frame: 5 years ]
  4. Clot lysis, patency and valve function [ Time Frame: 5 years ]
  5. Measurements of markers of coagulation and inflammation [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Objectively documented IFDVT
  • Acute stage IFDVT, complaints less than 14 days
  • Life expectancy longer than 6 months
  • First thrombus in the affected limb

Exclusion Criteria:

  • History of GI bleeding within 1 year
  • History of cardiovascular accident /central nervous system disease within 1 year
  • Severe hypertension (>180/100 mmHg)
  • Active malignancy
  • Major surgery within 6 weeks
  • Previous thrombosis of the affected limb (secondary thrombosis)
  • Varicosities/venous insufficiency Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) classification C3 or higher
  • Pregnancy
  • Immobility (wheelchair dependent)
  • Alanine aminotransferase (ALAT) > 3 times normal range
  • estimated Glomerular Filtration Rate (eGFR) < 30 mL/min

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970619


Locations
Layout table for location information
Netherlands
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6202 AZ
Academisch Medisch Centrum
Amsterdam, Netherlands
VuMC
Amsterdam, Netherlands
Haga Ziekenhuis
Den Haag, Netherlands
Nij Smellinghe
Drachten, Netherlands
Catharina Ziekenhuis Eindhoven
Eindhoven, Netherlands
MMC Eindhoven
Eindhoven, Netherlands
St Anna Ziekenhuis
Geldrop, Netherlands
Atrium MC Heerlen
Heerlen, Netherlands
Elkerliek Ziekenhuis
Helmond, Netherlands
St Antonius
Nieuwegein, Netherlands
Laurentius Roermond
Roermond, Netherlands
Maasstad ziekenhuis
Rotterdam, Netherlands
VieCuri
Venlo, Netherlands
Sint Jans Gasthuis
Weert, Netherlands
Isala klinieken
Zwolle, Netherlands
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Hugo ten Cate, MD, PhD Maastricht University Medical Centre
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT00970619    
Other Study ID Numbers: MEC 09-2-093
First Posted: September 2, 2009    Key Record Dates
Last Update Posted: March 6, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases